Research ArticleCancer

Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer

See allHide authors and affiliations

Science Translational Medicine  26 Jun 2019:
Vol. 11, Issue 498, eaaw4636
DOI: 10.1126/scitranslmed.aaw4636

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Solving cancer’s (vaso)pressing problem

Castration-resistant prostate cancer is a lethal late-stage form of prostate cancer, where the tumor can grow independently and no longer requires external stimulation of the androgen receptor. Zhao et al. found that the arginine vasopressin receptor 1a, which is normally associated with maintenance of blood pressure and fluid balance, can help activate signaling pathways involved in the development of castration resistance in prostate cancer. An antagonist of this receptor, relcovaptan, which can be safely used in humans, showed promising activity in mice modeling different stages of prostate cancer, suggesting this drug’s potential for repurposing if its effects are confirmed in clinical studies.

View Full Text

Stay Connected to
   Science Translational Medicine